12,372 trials
Alzheimer Disease · Cognitive Dysfunction · Mild Cognitive Impairment
Primary: Mean Change From Baseline to 24 Weeks in Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) Using the Average of Scores at 12, 18 and 24 Weeks. — -9.76…
Heavy Menstrual Bleeding · Uterine Fibroid
Primary: Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA — 73.4…
Recurrent or Metastatic NPC
Primary: IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 — 8.2; 21.4 months
Complications of Corneal Transplant
Primary: Endothelial Cell Loss Post EK for Donor Corneas Preserved in Life 4°C and Optisol GS Corneal Storage Media — 20; 18 % endothelial cell loss — p=< 0.05
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…
Diabetic Kidney Disease
Primary: The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure. — 458…
Graft-versus-host Disease (GVHD)
Primary: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host…
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Primary: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical Coronavirus Disease (COVID-19) With Seronegative Status With Onset at…
Enterovirus · Rhinovirus
Primary: Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint) — 122.5; 137.1 hours — p=0.4009
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -2.37; -2.55; -2.82; -1.29 percentage of HbA1c — p=<0.001
Anaemia
Primary: Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)…
Dry Eye
Primary: Coprimary Endpoint: Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 57 (Pre- to Post-CAE) — 1.38; 1.31; -0.47; -0.52 score on a scale — p=0.1871
Cardiovascular Diseases
Primary: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia…
Advanced Cholangiocarcinoma · Metastatic Cholangiocarcinoma
Primary: Progression Free Survival (PFS) as Determined by the Independent Radiology Committee (IRC) — 2.7; 1.4 months — p=<0.0001
COVID-19
Primary: Prevention of COVID-19 Complications or Death: During the 30-day Treatment Period, Time to First Occurrence of New/Worsened Organ Dysfunction During Index…